Erythropoietin-producing human hepatocellular carcinoma receptor B1 (EPHB1) is a member of the Eph family of receptor tyrosine kinases that mediate vascular system development. Eph receptor overexpression has been observed in various cancers and is related to the malignant transformation, metastasis, and differentiation of cancers, including hepatocellular carcinoma (HCC). Eph receptors regulate cell migration and attachment to the extracellular matrix by modulating integrin activity. EphrinB1, the ligand of EPHB1, has been shown to regulate HCC carcinogenesis. Here, we sought to determine whether EPHB1 polymorphisms are associated with hepatitis B virus (HBV)-infected liver diseases, including chronic liver disease (CLD) and HCC. We genotyped 26 EPHB1 single nucleotide polymorphisms (SNPs) in 399 Korean CLD, HCC, and LD (CLD+HCC) cases and seroconverted controls (HBV clearance, CLE) using the GoldenGate assay. Two SNPs (rs6793828 and rs11717042) and 1 haplotype that were composed of these SNPs were associated with an increased risk for CLD, HCC, and LD (CLD+HCC) compared with CLE. Haplotypes that could be associated with HBV-infected liver diseases by affecting downstream signaling were located in the Eph tyrosine kinase domain of EPHB1. Therefore, we suggest that EPHB1 SNPs, haplotypes, and diplotypes may be genetic markers for the progression of HBV-associated acute hepatitis to CLD and HCC.
Introduction
The single nucleotide polymorphism (SNP) is the most common genomic sequence variation and involves the stable substitution of a single base in the human genome. It was recently reported that various SNPs may increase susceptibility to risk factors for the development of a variety of cancers (Storey et al., 1998; Calin et al., 2005; Kiyohara & Yoshimasu, 2007; Dutt & Beroukhim, 2007; Zeng et al., 2006) . Moreover, SNPs in various genes, such as the genes for cell division cycle protein 6 (Cdc6) (Xiong et al., 2008) , patched homolog (PTCH) (Fu et al., 2008) , interleukin (IL)-10, IL-19, IL-20 (Truelove et al., 2008) , and Mdm2 p53 binding protein homolog (MDM2) (Yoon et al., 2008) , are associated with the risk of developing HCC. Consequently, specific SNPs can be used as genetic markers in patients with chronic liver diseases, including chronic hepatitis B (CHB) infections, liver cirrhosis (LC), and hepatitis B virus (HBV)-infected HCC.
HCC is one of the most common malignant tumors worldwide and causes about 1 million deaths each year (Parkin et al., 2001; Marrero, 2006) . The etiology of HCC seems to be multifactorial, and several events appear to be necessary for malignant transformation to occur. Hepatitis C virus (HCV) and HBV infections are important risk factors for chronic liver diseases (Collier & Sherman, 1998) . CHB infection is the most common etiology of HCC in Asian countries. In particular, cirrhosis is present in about 70% to 80% of HCC cases (Velazquez et al., 2003; Sy et al., 2005) . Moreover, HCC is a highly hypervascular tumor that is associated with a high faculty for vascular invasion (Sun & Tang, 2004) . Because tumor angiogenesis plays a critical role in the development and progression of cancers, including HCC (Sun & Tang, 2004; Pang & Poon, 2007) , angiogenic factors have been used not only for diagnosis and prognosis but also as predictors in cancer patients.
Erythropoietin-producing human hepatocellular carcinoma (Eph) receptors and ephrins are classified into the Ephrin-A or -B subfamily according to their structural homology and binding specificities. Eph receptors belong to the largest family of receptor tyrosine kinases, which contain an extracellular ephrin-binding domain and 2 fibronectin repeats, a transmembrane segment, and a cytoplasmic tyrosine kinase domain (Kalo & Pasquale, 1999) . Eph receptor signaling is even more complex and involves the downstream activation of Src family kinases. Eph receptors interact with many downstream adaptors, including phosphotyrosine-binding adaptor proteins, such as Nck, Crk, Grb2, and Grb10 (Kullander & Klein, 2002) . Importantly, Eph receptors and ephrins also regulate vascular development, tumorigenesis, and metastatic potential, as they are related to tumor growth and survival (Adams et al., 1999; Kojima et al., 2007; Kim et al., 2002) . In addition, Eph/ephrin overexpression increases angiogenesis and tumor vasculature formation in many human cancers (Adams et al., 1999; Tang et al., 1999) .
EphrinB ligands are transmembrane proteins that bind particularly to receptors of the EPHB subclass (Adams et al., 1999; Kojima et al., 2007) . EphrinB1 is overexpressed in HCC, suggesting an important role of the Eph/ephrin system in hepatocarcinogenesis or tumor progression (Dodelet & Pasquale, 2000) . The ephrinB1 ligand is known to bind to the EPHB1, EPHB2, and EPHB3 receptors, and the ectodomain of EPHB1 induces corneal angiogenesis (Brantley-Sieders & Chen, 2004) . Recent reports suggest that a direct functional link between EphB/ephrinB signaling and integrins participates in angiogenesis (Brooks et al., 1994a) .
Members of the integrin family of cell adhesion receptors play fundamental roles in angiogenesis. In particular, the integrin alpha v beta 3 is critical for angiogenesis and metastasis formation (Brooks et al., 1994b) , (Brooks et al., 1994a; Kikkawa et al., 2002) and is significantly upregulated in activated endothelial cells during angiogenesis (Hood & Cheresh, 2002) . Some alpha v integrins, particularly alpha v beta 3, are associated with tumor progression, including that of HCC . Despite these various findings, no study has addressed whether EPHB1 polymorphisms are associated with HCC. The aim of the present study was to determine whether EPHB1 polymorphisms are associated with susceptibility to CLD or HCC from acute hepatitis in a Korean population.
Methods

Subjects
This study included 86 HCC patients, 206 CLD patients, and 107 HBV clearance (CLE) patient controls. All subjects were of a genetically unrelated Korean population. All unrelated blood samples that were used in this study were obtained from the outpatient clinic of the Gastroenterology Department and from the Center for Health Promotion of Ajou University Hospital (Suwon, South Korea). This study was approved by the institutional review board.
Patients were classified into 3 groups-according to their HBV infection status, clinical data, and serological profile-as having CLE (spontaneous recovery or HBV eradication; n=107), CLD (including chronic hepatitis or liver cirrhosis, positivity for hepatitis B surface antigen [HBsAg (＋)] for more than 6 months, and no hepatocellular carcinoma; n=206), or HCC (n=86). Patients who were positive for anti-HCV or anti-HIV antibodies were excluded. Serological tests were performed using commercially available assays for HBsAg and hepatitis B e antigen (HBeAg), antibodies against hepatitis B core (HBcAb) and hepatitis B e, liver function tests for aspartate aminotransferase (AST or SGOT), alanine aminotransferase (ALT or SGPT), alpha-fetoprotein (AFP), and bilirubin levels.
The 107 CLE control patients, who were HBsAg (−), HBcAb (＋), and HBsAb (＋), presented with acute hepatitis from which they subsequently recovered without any sequelae. Patients with chronic hepatitis showed elevated ALT (≥2 times the upper limit of normal) at least 1 time during the follow-up period and were positive for HBV DNA, irrespective of HBeAg positivity. Patients with liver cirrhosis showed typical morphological findings on radiographic tests and corresponding laboratory features or evidence of portal hypertension. HCC was diagnosed if subjects fulfilled standard diagnostic criteria: either a serum AFP level ＞400 ng/ml in a patient who was known to have cirrhosis with hepatic masses as demonstrated on either ultrasonography or CT and diagnostic histology. The clinical characteristics of the study subjects are summarized in Table 1 .
Sample preparation
Blood samples were stored at −80 o C until use. Genomic DNA was purified using G-DEX blood genomic DNA (gDNA) purification kits (Intron Biotechnology Inc., SeungNam, Korea). The gDNA was quantified using the Picogreen dsDNA quantification reagent following a standard protocol (Molecular Probes, Eugene, OR, USA). The plates were read using a Victor TM 3 multilabel counter (PerkinElmer Inc. excitation 480 nm, emission 520 nm; PerkinElmer Inc., Waltham, MA, USA), and a standard curve for gDNA concentration was created using known concentrations of lambda DNA. Data are summarized as the mean±SD (standard deviation). CLE, HBV clearance; CLD, Chronic Liver Disease; HCC, Hepatocellular Carcinoma SNP selection and genotyping EPHB1 was selected for further analysis based on the gene expression data that were obtained by comparing adjacent normal tissues and HCC samples with the GenePlorer TwinChip Human-8K human cDNA microarray (Digital Genomics, Seoul, Korea). Validated SNPs in the EPHB1 gene were selected from a public SNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/). As shown in Figure 1 , there were 26 SNPs located in the 5 exons, 17 introns, and 4 5'-untranslated regions (UTRs) and flanking regions of EPHB1.
We selected intronic SNPs, for which genotyping was performed using the GoldenGate genotyping assay kit according to a standard protocol (Illumina Inc., San Diego, CA, USA). Briefly, 250 ng of gDNA was mixed with oligomers, and allele-specific extension was carried out by ramping the temperature from 70 
Statistical analysis
The goodness of fit of the χ 2 -test was used to compare the frequencies between the Korean (CLE) and Northeast Asian populations. Frequencies of the Northeast Asian population were from the Chinese and Japanese HapMap project data (http://hapmap.org). The χ 2 -test was used to check the Hardy-Weinberg equilibrium. Four genetic models (allele, additive, dominant, and recessive) that were proposed by Lewis (Lewis 2002) were assumed for the association test between the CLD and HCC groups. Linkage disequilibrium (LD) blocks were confirmed by Haploview software (version 
Results
SNP genotyping, allele frequencies, and LD blocks
The EPHB1 gene is located on chromosome 3q21-q23 and comprises 16 exons. We examined the association between SNPs of the EPHB1 gene and HBV-infected liver diseases. BeadStudio software (version 2.0) was used for genotype analysis, and logistic regressions were used for association tests. We genotyped a total of 26 polymorphisms in EPHB1, including 3 in exonic regions, 4 in the 5'-flanking regions, and 17 in intronic regions. Of the 26 genotyped SNPs, 13 were monomorphic, 9 were polymorphic, and 4 were nonpolymorphic. The genotype distributions of all SNPs in the CLE and CLD groups and all except 2 SNPs (rs2291989 and rs3772638) in the HCC group were in HardyWeinberg equilibrium (data not shown). The locations and reference SNP allele of the identified polymorphic sites are shown in Fig. 1A .
The CLE control group served as a representative of the Korean population. Minor frequencies of the SNPs in the CLE group were compared with other Northeast Asian populations, including Chinese (HCB) and Japanese (JPT) populations, which were genotyped in the International HapMap Project. All frequencies, except those of 2 SNPs (rs36185 and rs4955520), were similar between the Korean and HCB+JPT populations (rs6793828; KOR 0.402 HCB+JPT 0.361 p=0.407, rs11717042; KOR 0.383 HCB+JPT 0.350 p=0.496, Table 2 ).
A comparison between the LD blocks of the CLE group of the Korean and Northeast Asian populations showed the similar pattern of LD blocks in EPHB1 (Figs.  1, 2) . Moreover, the haplotype frequency patterns of HCB and JPT appeared to be the same as in our data (Table 2) . 
Association test of EPHB1 SNPs with HBV-infected liver diseases
With regard to genotypic association, we found that 2 SNPs (rs6793828 and rs11717042) were associated with HBV-infected liver diseases. The T allele of the SNP rs6793828 was associated with an increased risk of liver disease, 
EPHB1 haplotypes are associated with a risk for HBV-infected liver diseases
We found 3 LD blocks among the 9 polymorphic SNPs in EPHB1 that were constructed using the confidence interval method (Fig. 1B) . All of the SNPs in the LD block were tagging SNPs, and each LD block included 2 SNPs. Only the intronic regions of EPHB1 had 6 markers (rs9866494, rs3732567, rs2291989, rs3772638, rs6793828, and rs11717042) with haplotypes that were displayed. Two common haplotypes (frequency ＞0.1) in each block were used for further analysis. The haplotype frequencies and association tests are summarized in Table 4 . The low-frequency haplotypes were excluded from further analysis (data not shown). We identified a significant association between LD block3 and the risk for HBV-infected liver diseases, based on its 2 significant SNPs. Block3 had 3 haplotypes; in order of decreasing frequency, they were ht (C-A), ht (T-G), and ht (C-G). Except for the low-frequency haplotype (C-G), the frequencies with which each haplotype was present in the CLE, CLD, and HCC groups were estimated (Table 4) .
Block3-ht5 (C-A) showed a protective effect, with co- EPHB1 diplotypes are associated with a risk for HBV-infected liver diseases EPHB1 diplotypes were reconstructed based on the significant haplotypes of LD block3, and their frequencies were estimated (Table 5) . Association tests of low-fre- Logistic regression models were used for calculating odds ratios (95% confidential interval) and corresponding p-values for each SNP site and haplotype, controlling for age and sex as covariables using SAS. p-value of codominant, dominant, and recessive models also are given. Model; Allele (A vs a), codominant (AA vs Aa vs aa), dominant (AA vs Aa plus aa), and recessive (AA plus Aa vs aa) models. CLE, HBV clearance; CLD, Chronic Liver Disease; HCC, Hepatocellular Carcinoma; LD, CLD+HCC; OR, odds ratio; CI, confidence interval Bold indicates a case in which p＜0.05 quency diplotypes (＜0.1) were skipped. Diplotypes of the 2 EPHB1 haplotypes (C-A and T-G) were associated with HBV-infected liver diseases. The (C-A/C-A) diplotype had a more protective effect against HBV-infected liver diseases, including CLD and HCC, than the (T-G/T-G) diplotype. In addition, the (T-G/T-G) diplotype showed a greater relative risk effect for HBV-infected liver diseases than the (C-A/C-A) diplotype (Table 5) .
Discussion
In this study, we showed that the genetic polymor- ).
The 2 SNPs in EPHB1 that are associated with HBV-infected liver diseases, including CLD and HCC, are likely to be true risk factors due to their sufficient haplotype and diplotype effects (Table 4 , 5). Carriers of the ht5 (C-A) haplotype-containing variant alleles of these SNPs displayed protective effects (Table 4) . Furthermore, a significantly decreased risk also was observed for the ht5/ht5 (C-A/C-A) diplotype. In contrast, ht6 (T-G) and ht5/ht6 (C-A/T-G) displayed significant risk effects. Either of the 2 SNPs (rs6793828 and rs11717042) of EPHB1 may be candidates for a functional polymorphism that may affect gene expression and cancer aggressiveness.
Eph receptor tyrosine kinases initially were considered to be putative oncogenes, based on their overexpression in various human cancers, including HCC (Clifford et al., 2008; Chang et al., 2008; Oshima et al., 2008; Sawai et al., 2003) . EPHB1 SNPs have been shown to be associated with cancers, such as esophageal squamous cell carcinoma (ESCC) (Ng et al., 2008; Hu et al., 2005; Lesnick et al., 2007) , and previous studies identified the association of a significant SNP, rs6793828, with Parkinson disease (Lesnick et al., 2007) . Eph receptor "forward signaling" depends on the tyrosine kinase domain, which mediates adaptor protein phosphorylation and Eph receptor association with various proteins (Pasquale, 2008; Himanen & Nikolov, 2003a) . Other signaling proteins interact with Eph receptors and cause a variety of cellular effects, such as cell adhesion and migration (Castano et al., 2008) .
EPHB1 is a member of the Eph receptor family that mediates vascular development. Recently, the activation of endogenous EPHB1 receptors on renal microvascular endothelial cells by ephrinB1 was shown to induce tubule formation. EphrinB1 expression promotes tumor growth by initiating tumor angiogenesis in HCC (Valentini et al., 2003) . Interestingly, we found that the haplotypes were located in the Eph tyrosine kinase domain of EPHB1. The phosphorylated tyrosines of EPHB1 interact with the Src homology 2 domains of signaling molecules that are associated with HCC (Klein & Schneider, 1997; Yoon et al., 2001; Stein et al., 1998) , such as Src, growth factor receptor-bound protein 2 (Grb2), and Nck (Pasquale, 2008; Himanen & Nikolov, 2003a; Himanen & Nikolov, 2003b) . Thus, the LD region that contains ht6 (T-G), including some causative SNPs, may have synergistic and antagonistic effects on various downstream signaling proteins.
We suggest that ht6 (T-G) of EPHB1 is overrepresented in HBV-infected liver disease patients and that it potentially facilitates integrin alpha v beta 3-mediated increases in attachment of endothelial cells and activated integrin alpha v beta 3-regulated angiogenesis in HCC. These results provide the first evidence that functional ht6 (T-G) of EPHB1 is a genetic susceptibility factor for the development of CLD and HCC in a Korean population.
Angiogenesis plays an important role in the liver, and its role in HCC has been studied. Recently, it was reported that HCC and chronic HBV infection are associated with alpha v integrins . In particular, the beta 3 subset has been shown to mediate endothelial cell attachment (Huynh-Do et al., 1999) . The integrin alpha v beta 3 is expressed particularly by endothelial cells that are involved in angiogenesis, as its expression clearly is increased in proliferating vascular endothelial cells (Brooks et al., 1994a; Drake et al., 1995) .
Moreover, EPHB1 must be signaling-competent in order to mediate ephrinB1-induced attachment responses. The ephrinB1-induced increase in cell attachment suggests 'inside-out' activation of alpha v beta 3 in endothelial cells (Huynh-Do et al., 1999) . Eph receptors regulate cell attachment to the extracellular matrix by modulating integrin activity.
Taken together, our results show that EPHB1 SNPs, haplotypes, and diplotypes are relevant susceptibility markers for HBV-infected liver diseases. In previous studies, EPHB1 signaling has been shown to be associated with alpha v beta 3. SNPs and haplotypes of alpha v integrins are associated with HBV-infected HCC . Further studies are needed to demonstrate by gene-gene interactions that SNPs and haplotypes of EPHB1 and integrin alpha v are associated with HBV-infected liver diseases.
